plus 4, Talking Politics! - FOX News |
- Talking Politics! - FOX News
- January 2010 - Watertown Daily Times
- Poniard Pharma skids on picoplatin study data - Tacoma News Tribune
- WEB EXCLUSIVE JANUARY 25, 2 28PM - Grand Rapids Business Journal
- Personalized prescription - Boston Globe
| Posted: 25 Jan 2010 11:31 AM PST " Director Brian -- the judge frank -- major general Powell generally 664087669. We just concluded a -- minute interview with congressman John Boehner. The house minority leader who was here in our studio. We now proceed with with great joy to welcome back to our microphones congressman James Cliburn. Democrat of South Carolina the number three ranking Democrat in the house the house majority whip who was joined us many times. Congressman Cliburn welcome back to Brian and The Judge or. Just wanted to let you know that Boehner was just on -- it --" " Her -- her about the year but. --" " Yellow logo -- find out where you -- congressman -- listen to Chris Dodd and Evan -- And you know Chris Dodd says look we have the lawmakers really should take a breather for a month to six weeks. And -- before we go back to health care Evan Bayh thinks who leave the administration might -- misread. And the party the the mandating got. Last year but the administration wants to go forward without learning anything from Massachusetts. Where do you stand." " Well. But certain that we or oblivious to what happened in Massachusetts -- popular couple -- We have to be very very careful about the first of all. If you lose it's been issues in Massachusetts to the extent. That 98%. Of the citizens of that state that do have just injustice and impala built insurance really trying to make it possible for them before the United States. That's a fact. The candidate who won bill made it very clear. That he was against Obama planned but he voted for and supported the Massachusetts." " But as a result of his election. The symbolism. Of of replacing Ted Kennedy. With a Republican from Massachusetts a state that went for President Obama with a 26%. Cushion over John McCain. Have the Democrats in that congress been thrown into a state of disarray. Over what health care proposal can get through both houses." " Although Democrats intend to put mode that spot in symbols than substance maybe they have been. But I tend to deal -- over substance -- symbols. And on substantive issues this country that cannot expand its current. Problem -- here we cannot continue to see premiums double we cannot continue to allow women with breast cancer. To be -- from their current." " I know that this -- the priorities congressman you know give an example three to -- are hardly a right wing conservative. Came out and said here's would present Obama did wrong. There's two things wrong with health -- won the cost number two extending coverage 85% of Americans are affected by the cost. 15%. Don't have coverage the president focused on the 15% and -- was his mistake." " Well I don't agree with that and -- a number of times abusive on this show. When we came out of the box -- because what do. Seemed to go whale. In the campaign. We stated we have that lack of coverage sort of about me you know. For the -- whatever it is without -- talk about the people who do have cartridge. And women that they can keep that covers and what -- they can get. Paid good return on that coverage one political episode that was -- you know what the gentleman who talked about when the -- what is. Maybe inequities -- really because. He has they've never tried the use it. Tell them to try to use it -- outside the U. Reminds you a letter with twenty years and I've got breast cancer or my second treatment. Mistrust government to I would -- That's what we did not emphasize and now with a really. We admit it big must." " list. Last week your colleague. Mrs. Pelosi said that she simply lacked the votes to pass the Senate version. Of the bill that there are progressives who in the house. You know this better than we do congressman Cliburn who are adamant about a federal option. That there are pro life Democrats -- house were adamant that not a nickel go to abortion directly or indirectly. The Republicans now stand absolutely united against this if you. He had those Democrats who can't tolerate it. Plus the Republicans who don't believe the federal government should be regulating in this area of human behavior can't get through question. Where do you guys go next." " Well lamented -- Is that into the right. Or not to into making votes in the popular incentives. For the Senate passed plan and it has nothing to do with the public option it is they're going to do. Britain the breath you're compromise in this as to whether recalled that corn -- The corner of the thing. We are not going to pass this -- this -- stuff. For Nebraska or Louisiana or -- any other states of that mess up to Rio Vista plan report there was -- They'd be treated the same way I'm not coming back to the people -- a lot. And that's been the vote for me and that I important figure respect of the equipment raster that there are in my state. Bet big issue we don't -- respect that tax on these benefit plan to call them Cadillac let me call them. Which together. Good -- waited with -- That got a member policy that -- thousand dollars. And you -- of the Cadillac plant I don't think so we should not be put -- excess tax is that all these. Benefits by the and that's what. The -- gift and a few other things talk about." " Senator hatch said this over the weekend there's not one Republican who is against health care reform. And Mitch McConnell says Mr. President. Go to the middle and we will meet you there. I mean it doesn't seem -- they're just giving lip service and you know these guys personally it doesn't seem as though -- shutting the -- in the administration. You want you to call and." " Audible. What I don't know why you with the leadership of the when the mistress and a big." " No they're they're not I'm saying this shows they're not shutting the door in the administration." " The quote here yet to deal. That is one of my best friends are like ago last. Pets there's -- Are right on this. -- And tip egyptians and their retirement reached out the tip ball that they've done that not just with -- the same thing was been respected. -- of the house passed plan on Nokia. There were adopted. It would be fearful with the consent of the American people sit there like what we did and how -- 24%. When there's so what the Senate did. Over -- the American people like what we did without -- When this so that it did. There is that kids you know over and that's this into the -- themselves at the House of Lords and it'll seem do understand. That -- quality every two years. Stay -- to the American people we tend to respond to them a little bit. This that it would -- and so a lot of good if they pay a little more attention to what we -- on the house if for no other reason. That we are out there more often -- talks and we have much of the sensitivity of what people affected and but it seemed how --" Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| January 2010 - Watertown Daily Times Posted: 25 Jan 2010 10:27 AM PST
Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Poniard Pharma skids on picoplatin study data - Tacoma News Tribune Posted: 25 Jan 2010 09:58 AM PST Shares of Poniard Pharmaceuticals Inc. dropped Monday due to safety concerns about its experimental chemotherapy drug picoplatin. On Sunday, Poniard reported results from a midstage clinical study that compared picoplatin and other drugs to a standard chemotherapy regimen. It said the patients who received picoplatin had significantly less nerve damage from treatment than the patients who were given standard drugs. However, patients on the picoplatin regimen were more likely to develop two rare blood disorders, thrombocytopenia and neutropenia, and their symptoms were both more frequent and more severe than patients who took the other drugs. Thrombocytopenia is a condition in which people don't have enough blood platelets, which makes blood clotting difficult. Neutropenia is a decrease in a type of white blood cell. Poniard said patients treated with oxaliplatin did slightly better in terms of disease control, progression-free survival, and overall survival, compared with the picoplatin group. The study was not designed to determine if the difference was statistically significant. Picoplatin is intended to treat cancers as effectively as oxaliplatin but with less nerve damage. Poniard is testing an IV version of the drug as a treatment for prostate cancer and an oral version against solid tumors. Lazard Capital Markets analyst Joel Sendek said the blood disorder results are "potentially alarming." He said the survival results and the side effects show picoplatin is not an effective substitute for oxaliplatin. He noted that Poniard is low on cash and does not have any other drugs in clinical development. Sendek kept a "Sell" rating on Poniard shares, with a target price of $1. The shares have traded between $1.50 and $9.14 over the last year. In midday trading, shares of the South San Francisco, Calif., company sank 64 cents, or 24.5 percent, to $1.97. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| WEB EXCLUSIVE JANUARY 25, 2 28PM - Grand Rapids Business Journal Posted: 25 Jan 2010 11:31 AM PST VAIs growth, commitment raises it to Newsmaker of the Year
Vision, commitment, reputation and achievement translated into impact on patients, as well as economic development in Michigans growing health care and life sciences sector and in the $1 billion build-out of Grand Rapids unprecedented Medical Mile along Michigan Street combined to make the Van Andel Institute the clear choice for Grand Rapids Business Journals Newsmaker of the Year. VAI and its chairman and CEO, David Van Andel, accepted a plaque and medallion in recognition of the distinction during todays Economic Club of Grand Rapids luncheon before more than 400 attendees at the Amway Grand Plaza, Ambassador Ballroom. Selecting the top Newsmaker followed a discussion of more than 50 potential developments by the Business Journal editorial board, said Carole Valade, editor of the Business Journal. We spoke with economic analysts who reviewed the list of nominees with an eye toward the entities long-term economic impact on West Michigan, in particular. The accomplishments of Van Andel Institute and the role it is playing in the West Michigan economy enabled it to stand out at the top of the list. Its an honor to be recognized in this way for the second time. We received this distinction in 2000 when the life sciences industry was just coming into its own, Van Andel told the audience. To be presented with this at the start and finish of the decade shows we should be gratified with what has happened in those 10 years up on the hill. There has been more than $1 billion spent on the Medical Mile and yet there are so many things yet to be accomplished. Van Andel credited the wide range of cooperative efforts centered on private investment and philanthropy. This community gets it working together on so many different levels. As we watch the Medical Mile rise up, those relationships are important and the alliances will continue. The VAI is being recognized for its record of advancement during the past several months, as well as its ability to provide promise for long-term growth opportunities, said Business Journal Publisher John Zwarensteyn. This years Newsmaker nominees all made major contributions to the economic vitality of the West Michigan region. Comprising two units the Van Andel Educational Institute and the Van Andel Research Institute the nonprofit continued to foster scientific education for students from elementary school through doctoral studies, and housed basic research for treatments and cures for some of the most devastating diseases known to humankind. Several developments in 2009 produced quantum leaps forward for this star of the life sciences sector in West Michigan, which was founded in 1996 by the late Jay and Betty Van Andel. Jay Van Andel, the co-founder of Amway, suffered from Parkinsons disease and his wife, Betty, endured Alzheimers disease. Those two diseases, along with cancer, today form the major core of research activities performed at the VAI. In 2009, the VAI welcomed a cross-country partner and new research director. The VAI found a partner in the Translational Genomics Research Institute, known as TGen, of Phoenix. TGens leader, Jeffrey Trent, Ph.D., who had a major role in the groundbreaking Human Genome Project and is a former faculty member at the University of Michigan, replaced Dr. George Vande Woude, Ph.D., the renowned cancer researcher and founding chief scientific officer of the VARI. Trent founded TGen in 2002 to focus on translational research with an emphasis on discovering the molecular basis of disease and accelerating new drug development based on those discoveries. This affiliation concludes a search for George Vande Woudes successor, which has ended with the best possible result a renowned director leading Van Andel Research Institute and an alliance that strengthens two of the nations fast-emerging leaders in biomedical research, David Van Andel said at the time. This alliance demonstrates that VAI and TGen are at the forefront of redefining a borderless, collaborative, national and international scientific community that transcends geographical limitations. Vande Woude remains active in research at VARI as head of the Laboratory of Molecular Oncology. He was a top administrator for the National Cancer Institute when he agreed to be the first scientific leader at the VARI. Combining many of the scientific, educational, financial and business potentials of TGen and VARI will advance the research of both institutions and enhance the economic development of both Arizona and western Michigan, said Trent, who assumed his new role with the formal approval of the agreement in July. This alliance will elevate both organizations in the world of scientific research. In an internal move, the VAEI also welcomed a new leader. The year 2009 began with the announcement that Steve Triezenberg, Ph.D., dean of the VAI Graduate School and VARI scientific investigator, was replacing Gordon Van Harn as director. Van Harn retired after seven exemplary years of leading the VAEI, which followed a distinguished 30-year career as a professor at Calvin College. Prior to joining the VAI, Triezenberg spent 19 years on the faculty of MSUs department of biochemistry and molecular biology. Another major development occurred with the December opening of the $178 million, 240,000-square-foot Phase II expansion. With room to expand the number of labs from 18 to 50, lab space is nearly tripled, and included is the $4.2 million Jay Van Andel Parkinson Research Laboratory. Total square feet was brought to 400,000. Eventually, Phase II is expected to add 550 employees to the 250 already privileged to work there. The buildings that rise along Grand Rapids Medical Mile stand as a testament to our communitys ability to unite and work together, Van Andel said. Now is the time to harness that ability to another challenge: to fill those buildings with the most capable individuals who will enable West Michigan to take its place as a leader among emerging life sciences sectors. Students in the VAI Graduate School, a program that prepares Ph.D. scholars in cell and molecular genetics relevant to human disease, will use Phase II labs, along with faculty at the Michigan State University College of Human Medicine, which opens its new, nearby Secchia Center this year. MSU faculty will include five research clusters: cancer, obesity, cardiovascular disease, arthritis and neurobiology. Designed by New York-based Rafael Violy Architects PC, the buildings cascading roofs and windows are meant to recall the Grand River. Phase II was built to meet Leadership in Energy and Environmental Design specifications. It includes a 90-seat conference center and 100-seat cafeteria, a demonstration lab for visitors to view research in progress, an interactive Discovery Wall and an expanded library. In addition, the VAI provided an extreme makeover for neighboring city-owned Crescent Park, which serves not only the institutes employees, but a diverse cross-section of hospital workers, patients and students. Participating in the entire project were Owen-Ames-Kimball Co.; The Hunt Construction Group; Culhane & Fahrenkrug Consulting LLC; URS; Fishbeck, Thompson, Carr & Huber; Materials Testing Consultants; and CommTech Design. Some 1,800 construction jobs were associated with the addition. The research and recruitment ability the Phase II expansion provides will have a dramatic impact toward understanding disease and improving patient care, Trent said. Our increased research capacity coupled with our local, national and international collaborations in basic, translational and clinical research greatly increases the likelihood of discovering new ways to treat patients. That research was dramatically enhanced with several major new grant awards that point to the continued stellar reputation of this research leader in the Grand Rapids health care and life sciences landscape. A $6.2 million grant will bring a team of eight researchers from MSU and the University of Cincinnati to the VARI, including new MSU researchers Jack Lipton, Ph.D., and Caryl E. Sortwell, Ph.D. The grant will establish a prestigious Morris K. Udall Center of Excellence for Parkinsons research here in the summer with the arrival of center Director Timothy Collier, Ph.D., and Kathy Steece-Collier, Ph.D. It was awarded by the National Institute for Neurological Disorders and Stroke at the National Institutes of Health. Scientific Investigator Jeff MacKeigan, Ph.D, was awarded $1.3 million from the NIH for a five-year study of chemotherapy resistance in tumors, particularly in colon cancer. The study will examine the role of 13 enzymes discovered in MacKeigans lab, with a particular focus on one of them. The work could impact ovarian and breast cancers, as well. In addition, TGen is sharing an $18 million Stand Up 2 Cancer grant with the University of Pennsylvania for a three-year investigation of treatment alternatives for pancreatic cancer. Much of that work will occur in Arizona, but VARI Scientific Investigator Dr. Craig Webb, head of VARIs Program for Translational Medicine, will assist with the project. In addition, VAI announced a variety of research breakthroughs in the areas of herpes, breast cancer, pancreatic cancer, kidney cancer, acromegaly, bone marrow disease, myelodysplastic syndrome and plant enzymes. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Personalized prescription - Boston Globe Posted: 25 Jan 2010 12:35 PM PST "This is the most exciting thing in personalized medicine today, because Medco and CVS are big players with enormous impact in the field,'' said Edward Abrahams, executive director of the Personalized Medicine Coalition, an education and advocacy organization, which is funded by diagnostic, pharmaceutical, and health insurance companies, and hospitals, among others. "The point of personalized medicine is to develop better efficacy, better outcomes, fewer adverse events, and lower systemic costs. The pharmacy benefits manager is interested in all of those things.'' Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| You are subscribed to email updates from Add Images to any RSS Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment